Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Oncol ; 23(30): 7555-64, 2005 Oct 20.
Article in English | MEDLINE | ID: mdl-16234521

ABSTRACT

PURPOSE: Long-term survivors of successfully treated Hodgkin's lymphoma (HL) are at risk for late complications. Among these, infertility for female patients is of major importance. The subject of this analysis is to evaluate the menstrual status after HL therapy. PATIENTS AND METHODS: From 1994 to 1998, the German Hodgkin's Lymphoma Study Group conducted clinical trials for early-, intermediate-, and advanced-stage HL (trials HD7 to HD9) involving a total of 3,186 patients. A survey was carried out to evaluate the menstrual status after therapy. The following factors were assessed concerning their influence on amenorrhea: age, treatment, stage, and the use of oral contraceptives during chemotherapy. RESULTS: A total of 405 women aged younger than 40 years answered the study questions. After a median follow-up of 3.2 years, 51.4% of the women receiving eight cycles of dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) had continuous amenorrhea. Amenorrhea was significantly more frequent after dose-escalated BEACOPP compared with doxorubicin, bleomycin, vinblastine, and dacarbazine; cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine; or standard BEACOPP (P = .0066). Amenorrhea after therapy was most pronounced in women with advanced-stage HL (P < .0001), in women older than 30 years at treatment (P = .0065), and in women who did not take oral contraceptives during chemotherapy (P = .0002). CONCLUSION: Most women who are treated for advanced-stage HL experience amenorrhea after therapy. Amenorrhea is significantly more frequent in women with advanced-stage HL receiving eight cycles of dose-escalated BEACOPP and in women older than 30 years at first treatment. Furthermore, the data show a statistical association between the use of oral contraceptives and return of menstrual cycle, which is subject to further investigation.


Subject(s)
Amenorrhea/etiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Contraceptives, Oral , Hodgkin Disease/drug therapy , Adolescent , Adult , Age Factors , Aged , Bleomycin/therapeutic use , Combined Modality Therapy , Cyclophosphamide/therapeutic use , Dacarbazine/therapeutic use , Disease-Free Survival , Doxorubicin/therapeutic use , Etoposide/therapeutic use , Female , Hodgkin Disease/radiotherapy , Humans , Male , Menstrual Cycle , Middle Aged , Neoplasm Staging , Prednisone/therapeutic use , Procarbazine/therapeutic use , Risk Factors , Treatment Outcome , Vinblastine/therapeutic use , Vincristine/therapeutic use
2.
Int J Hematol ; 79(1): 74-8, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14979482

ABSTRACT

A prospective, randomized, controlled multicenter trial was performed to evaluate the efficacy and safety of once-daily oral monotherapy with 500 mg levofloxacin in comparison with 4.5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia. Low risk was defined by oral temperature > or = 38.5 degrees C on one occasion or > or = 38.0 degrees C twice within 24 hours and granulocytopenia < or = 500/microL for less than 10 days. The primary end point was defined as defervescence after 72 hours followed by at least 7 afebrile days. Secondary end points were overall response, time to defervescence, survival on day 30, and toxicity. Thirty-four episodes were included. Fever of unknown origin accounted for 26 (76.5%) of the episodes, microbiologically defined infection for 5 (14.7%) of the episodes, and clinically defined infection for 3 (8.8%) of the episodes. On an intent-to-treat basis, all episodes were evaluable for the primary end point. Levofloxacin and piperacillin/tazobactam were successful after 72 hours of treatment in 76.5% and 88.3% of the episodes. Overall response was achieved in 94.1% and 100% of the episodes, respectively. One inpatient in the oral treatment group died of septic shock without identification of a causative pathogen. A larger phase III trial is warranted to further evaluate the lack of inferiority of the oral monotherapy regimen versus standard intravenous therapy.


Subject(s)
Bacterial Infections/drug therapy , Drug Therapy, Combination/administration & dosage , Fever/etiology , Levofloxacin , Neutropenia/complications , Ofloxacin/administration & dosage , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/administration & dosage , Piperacillin/administration & dosage , Administration, Oral , Adult , Aged , Antineoplastic Agents/adverse effects , Bacterial Infections/etiology , Disease Susceptibility , Drug Administration Schedule , Drug Therapy, Combination/therapeutic use , Female , Fever/therapy , Fever of Unknown Origin/etiology , Fever of Unknown Origin/therapy , Humans , Immunocompromised Host , Male , Middle Aged , Neoplasms/complications , Neoplasms/drug therapy , Neutropenia/chemically induced , Ofloxacin/therapeutic use , Penicillanic Acid/therapeutic use , Piperacillin/therapeutic use , Prospective Studies , Safety , Tazobactam , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...